Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it will introduce a 400 mg version of oral antiviral FabiFlu®, for the treatment of mild to moderate COVID-19 in India. The Higher Strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day. A higher pill […]